Rising API Tariffs Are Forcing Pharma to Shift R&D Resources

FDAhealthcarelife sciencespharmaceuticalsPhRMA

Jun 16

In Part 3 of our interview; Lanton Law speaks with Applied Clinical Trials on the highlights of how tariffs on active pharmaceutical ingredients could affect resources for maintaining and accelerating R&D pipelines. The interview can be heard here.

pharmaceutical tariffstariffsactive pharmaceutical ingredientsR&DFDAClinical trials

Ron Lanton

Rising API Tariffs Are Forcing Pharma to Shift R&D Resources

FDA FY 2026 Biosimilar Plan: Key Insights for Manufacturers and Investors

Lanton Law Talks to Applied Clinical Trials About How FDA Cuts Are Creating New Bottlenecks in Clinical Operations